title: Clinical efficacy of intra-arterial pharmacokinetic chemotherapy with 5-fluorouracil, CDDP, gemcitabine, and angiotensin-II in patients with advanced pancreatic cancer.
abstract: OBJECTIVE
  To deliver anticancer drugs more selectively into cancer tissues and to improve survival time, we have developed a new method of intra-arterial chemotherapy for unresectable pancreatic cancer.
  
  
  METHODS
  From April 2002 to June 2006, twenty patients with pancreatic cancer with liver metastases were given intra-arterial infusions consisting of gemcitabine, 5-FU, and cisplatin mixed with angiotensin-II with the intent of increasing the blood flow into the tumor tissue but decreasing that to the non-tumor tissues. Simultaneously, tegafur/uracil was administered. A tumor marker and computed tomography (CT) findings were used to evaluate the efficacy of this chemotherapy.
  
  
  RESULTS
  The median survival was 365 days, and 6-months and 1-year survival rates were 80.0% and 44.7%, respectively. In 12 of 20 cases, the tumor marker level was decreased after this chemotherapy. In 10 of 20 cases, computed tomography showed a decrease in the tumor size. In 6 patients, back pain was the chief complaint and was reduced to a self-controlled level in 20 patients. No major complications were encountered.
  
  
  CONCLUSIONS
  Compared with the previously reported data in traditional chemotherapies, our method of intra-arterial chemotherapy appears to be quite useful not only for prolonging patient survival but also for improving the quality of life. Intra-arterial regional chemotherapy including changes in distribution of blood flow induced by angiotensin-II appears to be an effective palliative treatment for advanced pancreatic cancer.
authors.affiliation: Department of Gastroenterology, Saiseikai Niigata Second Hospital, Niigata, Japan. toruishi@ngt.saiseikai.or.jp
authors.forename: Toru
authors.initials: T
authors.lastname: Ishikawa
authors.forename: Hiroteru
authors.initials: H
authors.lastname: Kamimura
authors.forename: Atsunori
authors.initials: A
authors.lastname: Tsuchiya
authors.forename: Tadayuki
authors.initials: T
authors.lastname: Togashi
authors.forename: Kouji
authors.initials: K
authors.lastname: Watanabe
authors.forename: Kei-Ichi
authors.initials: K
authors.lastname: Seki
authors.forename: Hironobu
authors.initials: H
authors.lastname: Ohta
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Yoshida
authors.forename: Keiko
authors.initials: K
authors.lastname: Takeda
authors.forename: Tomoteru
authors.initials: T
authors.lastname: Kamimura
mesh_terms: D000804:Angiotensin II / Q000008:administration & dosage; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018395:CA-19-9 Antigen / Q000097:blood; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D018395:CA-19-9 Antigen; D003841:Deoxycytidine; D000804:Angiotensin II; D005472:Fluorouracil; D000093542:Gemcitabine